Thrombin inhibitors are a class of drugs used to treat and prevent blood clots by inhibiting thrombin. Thrombin is a serine protease found in blood plasma that converts soluble fibrinogen into insoluble strands of fibrin, and it positively feeds back on its own production. Thrombin inhibitors block this action, hindering the blood coagulation process. Some key applications of thrombin inhibitors include treating deep vein thrombosis, pulmonary embolism, atrial fibrillation, and arterial thrombosis.
The global thrombin inhibitor market is estimated to be valued at US$ 30.75 Bn in 2023 and is expected to exhibit a CAGR of 6.2% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
The thrombin inhibitor market is expected to witness significant growth over the forecast period owing to rising prevalence of cardiovascular diseases across the globe. According to the World Health Organization, cardiovascular diseases are the leading cause of death globally, accounting for over 17.9 million deaths in 2016. Growing geriatric population which is more susceptible to cardiovascular disorders is also driving the market growth. Moreover, increasing adoption of direct oral anticoagulants (DOACs) which have ease of use over traditional anticoagulants is positively impacting the market. DOACs such as rivaroxaban, apixaban, edoxaban and betrixaban directly inhibit thrombin and factor Xa activity providing more predictable response compared to vitamin K antagonists. However, factors such as lack of awareness regarding appropriate medications and regular monitoring can restrain the market growth during the forecast period.
SWOT Analysis
Strength: Thrombin inhibitor drugs help prevent dangerous blood clots from forming or expanding which can reduce the risk of heart attacks, strokes and other serious health issues. These drugs are very effective in prevention of clot formation and expansion and have strong clinical trial results. The global market for thrombin inhibitors is well established with wide range of products already available in the market.
Weakness: Thrombin inhibitor drugs comes with risk of serious bleeding issues if not taken as directed. The risk of bleeding complications increases if a patient takes them along with other blood thinning medications or supplements. These drugs also require regular monitoring of kidney and liver function tests to ensure safe usage. High cost of branded drugs also limits their widespread adoption.
Opportunity: Increasing number of patients being diagnosed with atrial fibrillation, deep vein thrombosis and other conditions leading to blood clots presents new opportunities for thrombin inhibitors market. Growing elderly population particularly in developed nations also increases susceptible patient pool. Approval of newer formulation with improved safety profile can boost the market. Expanding indications for existing drugs through additional clinical trials can drive future growth.
Threats: Expiry of key drug patents opens up market for cheaper generic competitors. Strong pipeline of alternative novel oral anticoagulants possessing improved safety profile poses pricing and market share threats. Stringent regulatory approval process and clinical trial requirements continue to be a major barrier.
Key Takeaways
The global thrombin inhibitor market is expected to witness high growth in the forecast period owing to rising prevalence of cardiovascular diseases, venous thromboembolism and atrial fibrillation. The global thrombin inhibitor market is estimated to be valued at US$ 30.75 Bn in 2023 and is expected to exhibit a CAGR of 6.2% over the forecast period 2023 to 2030.
Regional analysis: North America holds dominant share of the global thrombin inhibitor market currently owing to growing elderly population, strong healthcare infrastructure and availability of reimbursement. Asia Pacific region is expected witness fastest growth due to rising healthcare spending, large patient pool and increasing adoption of novel therapies. China and India are emerging as highly lucrative markets.
Key players: Key players operating in the thrombin inhibitor market are Pfizer Inc., Bristol Myers Squibb, Bayer AG, Sanofi S.A., Boehringer Ingelheim GmbH, Johnson & Johnson, Daiichi Sankyo Company, Limited, CSL Behring, Portola Pharmaceuticals, Inc., AbbVie Inc., GlaxoSmithKline plc, Novartis International AG, Merck & Co., Inc., Aspen Pharmacare Holdings Limited, Eisai Co., Ltd.
It is also used in diagnostic centers and clinics in various applications such as coagulation assays, defibrination of blood or plasma, and clotting factor tests.
R applications of human thrombin include several research activities such as protein-structure analysis, in vitro study, coagulation research, biochemical research, and medical research.Request Brochure –https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=39557The global human thrombin market can be segmented on the basis of product type, dosage form, and end-user.
A minimum activity of around 2,200-2,700 NIH units/mg is shown by the activated human thrombin when compared to NIH standard thrombin.
On the other hand, human β-thrombin and γ-thrombin are prepared from purified a-thrombin by limited proteolysis with TPCK-treated trypsin.
On the basis of end-users, it is segmented into hospitals, diagnostic and clinics, ambulatory surgical centers, and academic and research institutes.
Among the end-users, the hospital segment is anticipated to lead the market due to increase in the number of surgeries.
